Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study Meeting Abstract
| Authors: | Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S. E.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; To, I.; Huang, H.; Min, J.; Bolen, C. R.; Penuel, E.; Budde, E. L. |
| Abstract Title: | Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study |
| Meeting Title: | 2023 Lymphoma, Leukemia and Myeloma Congress |
| Journal Title: | American Journal of Hematology |
| Volume: | 98 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 18-21 |
| Meeting Location: | New York, NY |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2023-10-01 |
| Start Page: | S44 |
| Language: | English |
| ACCESSION: | WOS:001098086400071 |
| PROVIDER: | wos |
| DOI: | 10.1002/ajh.27112 |
| Notes: | Meeting Abstract: P-070 -- Source: Wos |
